Bristol-Myers Squibb (BMY) shares rebound after recent losses. Analysts weigh in on its value, growth potential, and updated ...

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...

(Reuters) -Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

Stocks capped a choppy day of trading on Wall Street with more losses Thursday after an early big tech rally faded and a ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

On July 24, 2025, the PTO Acting Director Coke Morgan Stewart discretionarily denied Amgen’s IPR2025-00601 and IPR2025-00602 challenging ...

Pfizer CEO Albert Bourla is expected to attend a $25 million fundraiser at US President Donald Trump’s golf club in ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.